Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N7O3S2.2CH4O3S |
| Molecular Weight | 705.847 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CS(O)(=O)=O.CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C5=CC=CC6=C5C=NN6)CC1
InChI
InChIKey=RFRIKACSFOTIMU-UHFFFAOYSA-N
InChI=1S/C23H27N7O3S2.2CH4O3S/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19;2*1-5(2,3)4/h2-4,13-14H,5-12,15H2,1H3,(H,24,27);2*1H3,(H,2,3,4)
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pictilisib is an oral potent inhibitor of class I PI3K with nanomolar activities against p110alpha, p110beta, p110delta, and p110gamma. The drug was developed for the treatment of solid tumors and reached phase II in patients with breast cancer and lung carcinoma, however its development was terminated.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . | 2008 Sep 25 |
|
| High-throughput screening compatible cell-based assay for interrogating activated notch signaling. | 2009 Feb |
|
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. | 2009 Jul |
|
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. | 2009 Jun 15 |
|
| Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. | 2010 Feb 1 |
|
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
| Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption. | 2010 Oct |
|
| Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. | 2010 Sep |
|
| Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. | 2010 Sep |
|
| Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. | 2010 Sep 8 |
|
| Targeting a common collaborator in cancer development. | 2010 Sep 8 |
|
| Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. | 2011 Jan 28 |
|
| Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
| PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. | 2012 |
|
| The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. | 2012 Apr 10 |
|
| Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. | 2012 Dec 15 |
|
| The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. | 2012 Feb |
|
| GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. | 2012 Jul 15 |
|
| Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. | 2012 May 17 |
|
| Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. | 2012 Oct |
|
| Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases. | 2012 Oct |
|
| Single cell network profiling assay in bladder cancer. | 2013 Apr |
|
| A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. | 2013 Feb 1 |
|
| Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. | 2013 Jan |
|
| Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. | 2013 Jan 17 |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
|
| The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. | 2014 Jan 16 |
|
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
Sample Use Guides
Patients with breast cancer receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with 260 mg pictilisib (daily on days 1-5 every week).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:21:10 GMT 2023
by
admin
on
Sat Dec 16 14:21:10 GMT 2023
|
| Record UNII |
G3D7HF2GS9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C82380
Created by
admin on Sat Dec 16 14:21:10 GMT 2023 , Edited by admin on Sat Dec 16 14:21:10 GMT 2023
|
PRIMARY | |||
|
56972143
Created by
admin on Sat Dec 16 14:21:10 GMT 2023 , Edited by admin on Sat Dec 16 14:21:10 GMT 2023
|
PRIMARY | |||
|
957054-33-0
Created by
admin on Sat Dec 16 14:21:10 GMT 2023 , Edited by admin on Sat Dec 16 14:21:10 GMT 2023
|
PRIMARY | |||
|
G3D7HF2GS9
Created by
admin on Sat Dec 16 14:21:10 GMT 2023 , Edited by admin on Sat Dec 16 14:21:10 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |